Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 44 for “"chimeric antigen receptor"”.

  1. Human Chimeric Antigen Receptor Macrophages For Cancer Immunotherapy

    Despite recent landmark advances in chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Myeloid cells are actively recruited to the tumor microenvironment (TME), where tumor associated macrophages (TAMs) …

    penn Repository record for Human Chimeric Antigen Receptor Macrophages For Cancer Immunotherapy (opens in a new tab)

  2. Development and characterisation of a novel chimeric antigen receptor against LGR5

    Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a target gene of the Wnt signalling pathway, is lowly expressed in some stem cell niches and overexpressed in multiple cancers, including pre-B acute lymphoblastic leukaemia (pre-B ALL), hepatocellular carcinoma (HCC) and …

    cambridge Repository record for Development and characterisation of a novel chimeric antigen receptor against LGR5 (opens in a new tab)

  3. Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma

    <p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …

    duke Repository record for Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma (opens in a new tab)

  4. Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment

    Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …

    mit Repository record for Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment (opens in a new tab)

  5. The dynamics of anti-tumour responses generated by chimeric antigen receptor-modified immune effector cells

    … and amplified in the laboratory to target antigens expressed on tumour cells through the introduction of chimeric antigen receptor (CAR) genes. Despite considerable advances in the treatment of B cell leukaemia using chimeric antigen receptor T (CART) cells targeting the CD19 antigen, some …

    unsw Repository record for The dynamics of anti-tumour responses generated by chimeric antigen receptor-modified immune effector cells (opens in a new tab)

  6. Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy

    Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …

    penn Repository record for Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy (opens in a new tab)

  7. Cord Blood-Derived Invariant Natural Killer T Cells as a Platform for Allogeneic Chimeric Antigen Receptor Cell Therapy

    <p>Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematopoietic malignancies achieving >50% complete response rates in numerous refractory/relapsed B cell malignancies. However, there are challenges that hinder CAR-T efficacy and bar the broader use of this therapy in …

    uthsc Repository record for Cord Blood-Derived Invariant Natural Killer T Cells as a Platform for Allogeneic Chimeric Antigen Receptor Cell Therapy (opens in a new tab)

  8. A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells

    <p> Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable results in the treatment of various hematological malignancies, ushering in tremendous innovation within the field of immunotherapy and improving patient outcomes. Despite this, CAR-T cell therapy is associated with a …

    uthsc Repository record for A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells (opens in a new tab)

  9. Tethered Il-15 to Augment The Therapeutic Potential of T Cells Expressing Chimeric Antigen Receptor: Maintaining Memory Potential, Persistence, and Antitumor Activity

    … the therapeutic potential of T cells expressing chimeric antigen receptor: Maintaining memory potential, persistence, and antitumor activity</strong></p> <p>Adoptive immunotherapy can retarget T cells to CD19, a tumor-associated antigen (TAA) expressed on B-cell malignancies, by the expression of …

    uthsc Repository record for Tethered Il-15 to Augment The Therapeutic Potential of T Cells Expressing Chimeric Antigen Receptor: Maintaining Memory Potential, Persistence, and Antitumor Activity (opens in a new tab)

  10. Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy

    … targets or explore mechanisms of resistance to Chimeric Antigen Receptor T-cell (CAR-T). Prior to conducting these screens, no identified murine GBM models were suitable for in vivo CRISPR/Cas9 screening, thus, a modified model was generated, the details of which are also included in this …

    mit Repository record for Utilizing in vivo genome-wide CRISPR/Cas9 screens in immunocompetent mouse models to identify novel tumor liabilities and explore mechanisms of resistance to Chimeric Antigen Receptor T-cell therapy (opens in a new tab)

  11. BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia

    … bispecific T-cell engaging antibody therapy and chimeric antigen receptor T-cell therapy, has proven an effective treatment for relapsed and refractory B-cell acute lymphoblastic leukemia in children. These new modalities, however, have also introduced new adverse side effects to the treatment …

    mit Repository record for BiTEs and CAR-Ts : immunotherapy in childhood B-cell acute lymphoblastic leukemia (opens in a new tab)

  12. Kir-Based Inhibitory Cars Overcome Car-Nk Cell Trogocytosis-Mediated Fratricide and Tumor Escape

    … tumor models and clinical data, we report that chimeric antigen receptor (CAR) activation in natural killer (NK) cells promoted the transfer of the CAR-cognate-antigen from tumor to NK cells, resulting in (1) lower tumor antigen density, thus impairing the ability of CAR-NK cells to engage with …

    uthsc Repository record for Kir-Based Inhibitory Cars Overcome Car-Nk Cell Trogocytosis-Mediated Fratricide and Tumor Escape (opens in a new tab)

  13. Modulating Avidity of H8F4-Car By Regulation of Expression Via Codon Modification

    … in the field of cancer immunotherapy and chimeric antigen receptor (CAR) therapies for the treatment of acute myeloid leukemia (AML), there is a need for more unique and innovative modalities to improve these therapies. Our group has extensively studied and demonstrated the potential of …

    uthsc Repository record for Modulating Avidity of H8F4-Car By Regulation of Expression Via Codon Modification (opens in a new tab)

  14. Development and Evaluation of a Potentially Wearable Device for Circulating Cell Monitoring

    … cancer metastasis and evaluating the efficacy of chimeric antigen receptor (CAR) T-cell therapies. Traditional blood-draw methods face challenges such as discontinuous monitoring and potential cell degradation, leading to inaccurate estimations. In vivo flow cytometry (IVFC), which measures …

    mit Repository record for Development and Evaluation of a Potentially Wearable Device for Circulating Cell Monitoring (opens in a new tab)

  15. In-vitro Glioblastoma Treatment Focusing on Convection Enhanced Delivery

    … methods like convection enhanced delivery and chimeric antigen receptor T cells (CAR-T) are promising treatments that can be translated to glioblastoma. In this study, CAR-T cell flow through a hydrogel was explored in the context of in-vitro convection enhanced delivery. A culture method to …

    vt Repository record for In-vitro Glioblastoma Treatment Focusing on Convection Enhanced Delivery (opens in a new tab)

  16. biological treatment options of multiple myeloma

    … proteosome inhibitors, monoclonal antibodies, Chimeric antigen receptor T cells, T cell engaging bispecific antibodies, antibody-drug conjugates along with steroids, and immunomodulatory therapies. Bortezomib, Carfilzomib, and Ixazomib are examples of proteasome inhibitors. Bortezomib is the …

    debrecen Repository record for biological treatment options of multiple myeloma (opens in a new tab)

  17. Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma

    … despite the advent of immunotherapies like chimeric antigen receptor (CAR) -T cells, which gained FDA approval in March 2021, relapse is nearly universally inevitable. The bone marrow (BM) microenvironment influences how MM cells survive, proliferate, and interact with stromal cells and how …

    gatech Repository record for Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma (opens in a new tab)

  18. Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies

    … malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape and improve outcomes after CAR T cell therapy. We …

    uthsc Repository record for Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies (opens in a new tab)

  19. The Impact of IL-9 on Disease in Murine Models of Systemic Lupus Erythematosus

    … to the isotype control. In parallel, we used a chimeric antigen receptor (CAR)-T cell approach, which is a promising treatment option for SLE patients, to test whether a third generation CAR-T cell can be polarized to a CAR-T9 cell and mitigate SLE disease severity. Our preliminary results …

    iupui Repository record for The Impact of IL-9 on Disease in Murine Models of Systemic Lupus Erythematosus (opens in a new tab)

  20. Mathematical Modelling of Immuno-Oncology and Related Immunology

    … and the next. Here we look specifically at Chimeric Antigen Receptor (CAR)-T cell therapy, explore the mechanisms by which this living drug grows and changes inside the body, and explore how and why this process differs so dramatically between patients. </p><p>We develop two ordinary …

    duke Repository record for Mathematical Modelling of Immuno-Oncology and Related Immunology (opens in a new tab)

Page 1 of 3